Practice of Epidemiology Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort

Longitudinal observational data are required to assess the association between exposure to β-interferon medications and disease progression among relapsing-remitting multiple sclerosis (MS) patients in the "real-world" clinical practice setting. Marginal structural Cox models (MSCMs) can provide distinct advantages over traditional approaches by allowing adjustment for time-varying confounders such as MS relapses, as well as baseline characteristics, through the use of inverse probability weighting. We assessed the suitability of MSCMs to analyze data from a large cohort of 1,697 relapsing-remitting MS patients in British Columbia, Canada (1995-2008). In the context of this observational study, which spanned more than a decade and involved patients with a chronic yet fluctuating disease, the recently proposed "normalized stabilized" weights were found to be the most appropriate choice of weights. Using this model, no association between β-interferon exposure and the hazard of disability progression was found (hazard ratio = 1.36, 95% confidence interval: 0.95, 1.94). For sensitivity analyses, truncated normalized unstabilized weights were used in additional MSCMs and to construct inverse probability weight-adjusted survival curves; the findings did not change. Additionally, qualitatively similar conclusions from approximation approaches to the weighted Cox model (i.e., MSCM) extend confidence in the findings.

[1]  P. Gustafson,et al.  Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study , 2014, European journal of neurology.

[2]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[3]  R. Ali,et al.  On computing standard errors for marginal structural Cox models , 2014, Lifetime data analysis.

[4]  Michal Abrahamowicz,et al.  Comparison of Approaches to Weight Truncation for Marginal Structural Cox Models , 2013 .

[5]  P. Gustafson,et al.  Interferon beta and long-term disability in multiple sclerosis. , 2013, JAMA neurology.

[6]  E. Frohman,et al.  Interferon beta and long-term disability in multiple sclerosis--reply. , 2013, JAMA neurology.

[7]  P. Calabresi,et al.  Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. , 2013, JAMA neurology.

[8]  W G Havercroft,et al.  Simulating from marginal structural models with time‐dependent confounding , 2012, Statistics in medicine.

[9]  J. Petkau,et al.  Treatment With Interferon Beta for Multiple Sclerosis—Reply , 2012 .

[10]  D. Goodin,et al.  Treatment with interferon beta for multiple sclerosis. , 2012, JAMA.

[11]  S. Cole,et al.  A simulation study of finite‐sample properties of marginal structural Cox proportional hazards models , 2012, Statistics in medicine.

[12]  Wei Zhong,et al.  Assessing mediation using marginal structural models in the presence of confounding and moderation. , 2012, Psychological methods.

[13]  P. Gustafson,et al.  Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.

[14]  L. Kappos,et al.  Evaluating the potential benefit of interferon treatment in multiple sclerosis. , 2012, JAMA.

[15]  Stephen R Cole,et al.  Estimating the Effects of Multiple Time-varying Exposures Using Joint Marginal Structural Models: Alcohol Consumption, Injection Drug Use, and HIV Acquisition , 2012, Epidemiology.

[16]  S. Cole,et al.  Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death. , 2012, American journal of epidemiology.

[17]  Edward A. Smith,et al.  Introducing the At-Risk Average Causal Effect with Application to HealthWise South Africa , 2012, Prevention Science.

[18]  Samy Suissa,et al.  The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding , 2012, European Journal of Epidemiology.

[19]  M. J. van der Laan,et al.  Colon Cancer Survival With Herbal Medicine and Vitamins Combined With Standard Therapy in a Whole-Systems Approach , 2011, Integrative cancer therapies.

[20]  M. J. van der Laan,et al.  Lung Cancer Survival With Herbal Medicine and Vitamins in a Whole-Systems Approach , 2011, Integrative cancer therapies.

[21]  Hansjakob Furrer,et al.  A sequential Cox approach for estimating the causal effect of treatment in the presence of time‐dependent confounding applied to data from the Swiss HIV Cohort Study , 2010, Statistics in medicine.

[22]  D. Goodin,et al.  Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  S. Cole,et al.  Time scale and adjusted survival curves for marginal structural cox models. , 2010, American journal of epidemiology.

[24]  Michal Abrahamowicz,et al.  The International Journal of Biostatistics CAUSAL INFERENCE Accuracy of Conventional and Marginal Structural Cox Model Estimators : A Simulation Study , 2011 .

[25]  F. Dekker,et al.  The International Journal of Biostatistics Comparing Mortality in Renal Patients on Hemodialysis versus Peritoneal Dialysis Using a Marginal Structural Model , 2011 .

[26]  Jessica G. Young,et al.  Relation between three classes of structural models for the effect of a time-varying exposure on survival , 2010, Lifetime data analysis.

[27]  S. Cole,et al.  Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death. , 2010, American journal of epidemiology.

[28]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[29]  J. Robins,et al.  Estimation and extrapolation of optimal treatment and testing strategies , 2008, Statistics in medicine.

[30]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[31]  J. Fisk,et al.  How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? , 2007, Neurology.

[32]  S. Suissa,et al.  Immortal time bias in the study of effectiveness of interferon‐β in multiple sclerosis , 2008, Annals of neurology.

[33]  Yinshan Zhao,et al.  Relapses in multiple sclerosis are age- and time-dependent , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[34]  G. Filippini,et al.  Interferon‐β treatment and the natural history of relapsing‐remitting multiple sclerosis , 2008, Annals of neurology.

[35]  M. Trojano,et al.  New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .

[36]  J. Robins,et al.  Estimating causal effects from epidemiological data , 2006, Journal of Epidemiology and Community Health.

[37]  D. Paty,et al.  Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.

[38]  Jay S. Kaufman,et al.  Methods in social epidemiology , 2006 .

[39]  M. Glymour,et al.  USING CAUSAL DIAGRAMS TO UNDERSTAND COMMON PROBLEMS IN SOCIAL EPIDEMIOLOGY , 2006 .

[40]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[41]  A. Alheraish,et al.  Design and implementation of home automation system , 2004, IEEE Transactions on Consumer Electronics.

[42]  M. J. van der Laan,et al.  Analysis of longitudinal marginal structural models. , 2004, Biostatistics.

[43]  M. Hernán,et al.  Controlling for Time-dependent Confounding using Marginal Structural Models , 2004 .

[44]  James M. Robins,et al.  Association, Causation, And Marginal Structural Models , 1999, Synthese.

[45]  J. Robins,et al.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. , 2003, American journal of epidemiology.

[46]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[47]  S. Cole,et al.  Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. , 2002, American journal of epidemiology.

[48]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[49]  J. Robins,et al.  Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .

[50]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[51]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[52]  D. Berry,et al.  Statistical models in epidemiology, the environment, and clinical trials , 2000 .

[53]  James M. Robins,et al.  Marginal Structural Models versus Structural nested Models as Tools for Causal inference , 2000 .

[54]  Evidence of interferon β-1a dose response in relapsing-remitting MS , 1999, Neurology.

[55]  D. Rubin,et al.  Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. Commentary. Authors' reply , 1999 .

[56]  G. Shaw,et al.  Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .

[57]  Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. , 1999, Neurology.

[58]  J. Pearl,et al.  Causal diagrams for epidemiologic research. , 1999, Epidemiology.

[59]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[60]  Terry M. Therneau,et al.  Extending the Cox Model , 1997 .

[61]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[62]  Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. , 1995, Neurology.

[63]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[64]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[65]  R B D'Agostino,et al.  Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. , 1990, Statistics in medicine.

[66]  D. Paty,et al.  Scales for rating impairment in multiple sclerosis , 1988, Neurology.

[67]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[68]  Richard D. Gill,et al.  Understanding Cox's regression model: a martingale approach : (preprint) , 1984 .

[69]  W. A. Thompson,et al.  On the treatment of grouped observations in life studies. , 1977, Biometrics.

[70]  D. Horvitz,et al.  A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .